Duvortuxizumab

DB15211InvestigationalProtein Based Therapies

Duvortuxizumab is under investigation in clinical trial NCT02743546 (Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma).

Mechanism: Pharmacologically active on B-lymphocyte antigen CD19 and T-cell surface glycoprotein CD3
Curator reviewed

Resolves to

Compound

UNIIJ545GSE96YCAS1831098-91-9

Targets

P15391CD19

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Duvortuxizumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account